Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]
Proposed [GID-TA10791] Expected publication date: TBC
Search results
793 results
-
-
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]
Proposed [GID-TA10795] Expected publication date: TBC
-
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]
Proposed [GID-TA10792] Expected publication date: TBC
-
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]
Proposed [GID-TA10796] Expected publication date: TBC
-
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]
Proposed [GID-TA10793] Expected publication date: TBC
-
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]
Proposed [GID-TA10797] Expected publication date: TBC
-
Brolucizumab for treating diabetic macular oedema [ID3902]
Proposed [GID-TA10794] Expected publication date: TBC
-
Faricimab for treating diabetic macular oedema [ID3899]
Proposed [GID-TA10798] Expected publication date: TBC
-
Faricimab for treating wet age-related macular degeneration [ID3898 ]
Proposed [GID-TA10799] Expected publication date: TBC
-
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Proposed [GID-TA10800] Expected publication date: TBC
-
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]
Proposed [GID-TA10801] Expected publication date: TBC
-
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492) ID3777
Proposed [GID-TA10810] Expected publication date: 22 October 2021
-
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]
Proposed [GID-TA10453] Expected publication date: TBC
-
Dulaglutide for treating type 2 diabetes [ID1451]
Proposed [GID-TA10439] Expected publication date: TBC
-
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Proposed [GID-TA10553] Expected publication date: TBC
-
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)
Proposed [GID-TA10306] Expected publication date: TBC
-
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]
Proposed [GID-TA10574] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]
Proposed [GID-TA10811] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]
Proposed [GID-TA10813] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]
Proposed [GID-TA10814] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3933]
Proposed [GID-TA10815] Expected publication date: TBC
-
Mosunetuzumab for treating relapsed or refractory B-cell non-Hodgkin lymphoma [ID3931]
Proposed [GID-TA10816] Expected publication date: TBC
-
Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]
Proposed [GID-TA10817] Expected publication date: TBC
-
Tofacitinib for treating active ankylosing spondylitis [ID3865]
Proposed [GID-TA10771] Expected publication date: TBC
-
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]
Proposed [GID-TA10732] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Proposed [GID-TA10777] Expected publication date: TBC
-
Romosozumab for treating severe osteoporosis [ID3936]
Proposed [GID-TA10828] Expected publication date: TBC
-
Nitisinone for treating alkaptonuria [ID2691]
Proposed [GID-TA10659] Expected publication date: TBC
-
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]
Proposed [GID-TA10600] Expected publication date: 22 December 2021
-
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Proposed [GID-TA10826] Expected publication date: TBC
-
Benralizumab for previously treated severe nasal polyps [ID1659]
Proposed [GID-TA10818] Expected publication date: TBC
-
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]
Proposed [GID-TA10812] Expected publication date: TBC
-
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]
Proposed [GID-TA10676] Expected publication date: 27 April 2022
-
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Proposed [GID-TA10764] Expected publication date: 26 January 2022
-
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]
Proposed [GID-TA10753] Expected publication date: TBC
-
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]
Proposed [GID-TA10749] Expected publication date: TBC
-
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Proposed [GID-TA10657] Expected publication date: TBC
-
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]
Proposed [GID-TA10535] Expected publication date: TBC
-
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Proposed [GID-TA10763] Expected publication date: TBC
-
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]
Proposed [GID-TA10660] Expected publication date: TBC
-
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]
Proposed [GID-TA10746] Expected publication date: TBC
-
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Proposed [GID-TA10733] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Proposed [GID-TA10757] Expected publication date: TBC
-
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]
Proposed [GID-TA10821] Expected publication date: TBC
-
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Proposed [GID-TA10822] Expected publication date: TBC
-
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Proposed [GID-TA10823] Expected publication date: TBC
-
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]
Proposed [GID-TA10824] Expected publication date: TBC
-
Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]
Proposed [GID-TA10738] Expected publication date: TBC
-
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]
Proposed [GID-TA10737] Expected publication date: TBC
-
Liposomal bupivacaine for treating postoperative pain [ID3799]
Proposed [GID-TA10681] Expected publication date: TBC